Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have emerged as a cornerstone of treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer. Here, CDK4 is linked to breast carcinoma.